Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Erasca Inc (NQ: ERAS ) 2.720 +0.130 (+5.02%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Erasca Inc Erasca Reports First Quarter 2024 Business Updates and Financial Results May 08, 2024 From Erasca, Inc. Via GlobeNewswire Erasca Announces $45 Million Oversubscribed Private Placement Financing March 27, 2024 Funding from new and existing investors extends anticipated cash runway into H2 2026 From Erasca, Inc. Via GlobeNewswire Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results March 27, 2024 From Erasca, Inc. Via GlobeNewswire Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials February 14, 2024 From Erasca, Inc. Via GlobeNewswire Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From Erasca, Inc. Via GlobeNewswire Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Erasca, Inc. Via GlobeNewswire Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma December 11, 2023 From Erasca, Inc. Via GlobeNewswire Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway November 28, 2023 From Erasca, Inc. Via GlobeNewswire Erasca Reports Third Quarter 2023 Financial Results and Business Updates November 09, 2023 From Erasca, Inc. Via GlobeNewswire Erasca to Present at Upcoming Investor Conferences in November November 08, 2023 From Erasca, Inc. Via GlobeNewswire Erasca to Present at the Cantor Global Healthcare Conference September 19, 2023 From Erasca, Inc. Via GlobeNewswire Erasca Reports Second Quarter 2023 Financial Results and Business Updates August 10, 2023 From Erasca, Inc. Via GlobeNewswire Erasca Reports First Quarter 2023 Financial Results and Business Updates May 15, 2023 From Erasca, Inc. Via GlobeNewswire Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates March 23, 2023 From Erasca, Inc. Via GlobeNewswire Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From Erasca, Inc. Via GlobeNewswire Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors December 20, 2022 From Erasca, Inc. Via GlobeNewswire Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors December 13, 2022 ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activity From Erasca, Inc. Via GlobeNewswire Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib December 09, 2022 From Erasca, Inc. Via GlobeNewswire Erasca Announces Pricing of Underwritten Offering of Common Stock December 09, 2022 From Erasca, Inc. Via GlobeNewswire Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination November 30, 2022 From Erasca, Inc. Via GlobeNewswire Erasca to Present at Upcoming Investor Conferences November 22, 2022 From Erasca, Inc. Via GlobeNewswire Erasca Reports Third Quarter 2022 Financial Results and Business Updates November 09, 2022 From Erasca, Inc. Via GlobeNewswire Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination October 20, 2022 From Erasca, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
